Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Friday 17 October, 2008

Lipoxen PLC

Additional Listing

RNS Number : 9979F
Lipoxen PLC
17 October 2008
 



Lipoxen PLC

('Lipoxen' or 'the Company')


Additional listing


London, UK, 17 October 2008 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and oncology drugs, announces that application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 135,658 ordinary shares of 0.5p each (the 'New Ordinary Shares').


The New Ordinary Shares are being admitted pursuant to the exercise of options under the Lipoxen Plc Unapproved Share Option Plan.


It is expected that dealing in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 21 October 2008.


Enquiries 


Lipoxen PLC


M. Scott Maguire, Chief Executive Officer

Colin Hill, Finance Director

+44 (0)20 7691 3583 



Teathers Ltd (nominated adviser)


Shaun Dobson / Claes Spång 

+44 (0)20 7426 9000



Citigate Dewe Rogerson

 

+44 (0)20 7638 9571

David Dible / Heather Keohane





This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISEAEEKFDAPFFE